NDAORALTABLETPriority Review
Approved
Aug 1978
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
5/8 — Partial
Priority Review
LOPRESSOR (metoprolol tartrate) by Bausch Health is 1 -selective (cardioselective) adrenergic receptor blocking agent. Approved for hypertension in adult patients, to lower blood pressure, the long-term treatment of angina pectoris and 7 more indications. First approved in 1978.
Drug data last refreshed 10h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LOPRESSOR (metoprolol tartrate) is a cardioselective beta-1 adrenergic receptor blocking agent approved in 1978 for oral use. It treats hypertension, angina pectoris, and acute myocardial infarction by reducing cardiac workload and oxygen demand through competitive antagonism of catecholamines at cardiac adrenergic sites.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30%), indicating shrinking team investment and focus on generic transition planning.
Mechanism of Action
1 -selective (cardioselective) adrenergic receptor blocking agent. This preferential effect is not absolute, however, and at higher plasma concentrations, metoprolol also inhibits beta 2 -adrenoreceptors, chiefly located in the bronchial and vascular musculature. Metoprolol has no intrinsic…
Indications (9)
Worked on LOPRESSOR at Bausch Health? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.